Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
ROBOZ, GJ; H DOHNER; C POCOCK; H DOMBRET; F RAVANDI et. al.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
Autoři
ROBOZ, GJ; H DOHNER; C POCOCK; H DOMBRET; F RAVANDI; JH JANG; D SELLESLAG; Jiří MAYER; UM MARTENS; J LIESVELD; T BERNAL; MC WANG; PW YU; L SHI; S GUO; Torre I LA; B SKIKNE; Q DONG; J BRAVERMAN; SA NEHME; CL BEACH a AH WEI
ROBOZ, GJ; H DOHNER; C POCOCK; H DOMBRET; F RAVANDI; JH JANG; D SELLESLAG; Jiří MAYER; UM MARTENS; J LIESVELD; T BERNAL; MC WANG; PW YU; L SHI; S GUO; Torre I LA; B SKIKNE; Q DONG; J BRAVERMAN; SA NEHME; CL BEACH a AH WEI. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, roč. 106, č. 12, s. 3240-3244. ISSN 0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2021.279174.
@article{1816323, author = {Roboz, GJ and Dohner, H and Pocock, C and Dombret, H and Ravandi, F and Jang, JH and Selleslag, D and Mayer, Jiří and Martens, UM and Liesveld, J and Bernal, T and Wang, MC and Yu, PW and Shi, L and Guo, S and La, Torre I and Skikne, B and Dong, Q and Braverman, J and Nehme, SA and Beach, CL and Wei, AH}, article_location = {PAVIA}, article_number = {12}, doi = {https://doi.org/10.3324/haematol.2021.279174}, language = {eng}, issn = {0390-6078}, journal = {haematologica}, note = {Bez afiliace k MU.}, title = {Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial}, volume = {106}, year = {2021} }
TY - JOUR ID - 1816323 AU - Roboz, GJ - Dohner, H - Pocock, C - Dombret, H - Ravandi, F - Jang, JH - Selleslag, D - Mayer, Jiří - Martens, UM - Liesveld, J - Bernal, T - Wang, MC - Yu, PW - Shi, L - Guo, S - La, Torre I - Skikne, B - Dong, Q - Braverman, J - Nehme, SA - Beach, CL - Wei, AH PY - 2021 TI - Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial JF - haematologica VL - 106 IS - 12 SP - 3240-3244 EP - 3240-3244 PB - FERRATA STORTI FOUNDATION SN - 03906078 N1 - Bez afiliace k MU. ER -
ROBOZ, GJ; H DOHNER; C POCOCK; H DOMBRET; F RAVANDI; JH JANG; D SELLESLAG; Jiří MAYER; UM MARTENS; J LIESVELD; T BERNAL; MC WANG; PW YU; L SHI; S GUO; Torre I LA; B SKIKNE; Q DONG; J BRAVERMAN; SA NEHME; CL BEACH a AH WEI. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2021, roč.~106, č.~12, s.~3240-3244. ISSN~0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2021.279174.